{"data":{"id":641,"lang":"en","title":"UCL Scientists Identify Protein That Triggers Diabetic Blindness Years Before Current Treatments Can Act","summary":"UCL researchers discovered the LRG1 protein triggers diabetic blindness far earlier than known, opening a new path to prevention.","category":"science","category_label":"Science","published_at":"2026-03-08T01:02:11Z","updated_at":"2026-03-08T01:02:11Z","url":"https://techtools.cz/tools/news/article/641-ucl-scientists-identify-protein-that-triggers-diabetic-blindness-years-before","api_url":"https://techtools.cz/news-api/v1/articles/641?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/641.md?lang=en","image_url":"https://ophthalmologybreakingnews.com/files/images/blog_early-protein-trigger-of-diabetic-retinopathy-identified-by-ucl-scientists.jpg","word_count":163,"reading_time_minutes":1,"sources":[{"url":"https://ophthalmologybreakingnews.com/early-protein-trigger-of-dr-identified","domain":"ophthalmologybreakingnews.com"},{"url":"https://www.sciencedaily.com/releases/2026/03/260306224225.htm","domain":"sciencedaily.com"}],"translation":null,"content":"Researchers at UCL Institute of Ophthalmology have identified a protein called LRG1 as the key trigger of diabetic retinopathy, a leading cause of vision loss among working-age adults worldwide. The study, published in Science Translational Medicine, shows LRG1 constricts tiny retinal blood vessels and cuts oxygen supply much earlier in the disease than previously understood.\n\nCurrent treatments target a different protein called VEGF, but these therapies only work for about 50% of patients and typically cannot reverse existing damage. In diabetic mice, blocking LRG1 prevented early retinal damage and preserved eye function entirely. \"Our discovery shows that diabetic eye disease starts earlier than we thought, and LRG1 is a key culprit,\" said lead author Dr. Giulia De Rossi.\n\nAn LRG1-targeting therapeutic developed by the UCL team is now in pre-clinical studies, with human trials planned. Professor Emeritus Stephen Moss noted it \"could provide an effective new option for patients, especially those in the early stages of disease who don't respond to existing treatments.\""}}